Pinsent Masons continues its expansion in Dublin office

15 Jul 2019 | 11:23 am | 1 min. read

Pinsent Masons continues its expansion in Dublin office with Life Sciences and Technology Litigation hire

International law firm Pinsent Masons has boosted its pan European life sciences and technology sector capabilities with the appointment of Michael Finn as partner in its Dublin office.


Michael will be joining from Matheson, where he leads its IP disputes group and previously established its life sciences regulatory and litigation practice.

 

 Michael advises on complex domestic and international commercial disputes, contentious intellectual property matters, data privacy disputes, regulatory matters including prosecutions, product liability, and judicial review. He has extensive experience in large-scale litigation before the Irish Commercial Court.

 

 A valuable addition to the Dublin IP and data team, he will work alongside IP and data litigation specialist Ann Henry to enhance the firm's Big Pharma offering in Dublin.

 

Clare Tunstall, Head of Life Sciences at Pinsent Masons said:

 "We are continuing to invest in appointing talented individuals who bolster our ability to service our international client base. Pinsent Masons has a pan European team of lawyers specialising in Life Sciences & Healthcare who advise across a range of IP, transactional and regulatory matters and Michael's stellar reputation and experience makes him a fantastic addition to our team."

 

During his career, Michael has acted for some of the largest organisations in the Life Sciences and technology sectors. His work includes advising technology companies on the convergence of tech, life sciences and medical device laws. He has acted in IP litigation for some of the world’s best known technology brands, and has advised one of the world’s largest life sciences companies in the defence of product liability litigation relating to a market-leading immunology product. 

 

 Gayle Bowen, Head of Pinsent Masons' Dublin office adds:

 "Michael is a recognised leading practitioner who brings sector knowledge and expertise that is unmatched in the Irish market. His diverse experience complements Pinsent Masons' international Advanced Manufacturing and Technology sector and is a valuable addition to our Dublin office."

 

 Michael's appointment continues the expansion of Pinsent Masons' Dublin office, and follows the firm's recent recruitment of Corporate Financial Services partner Naoise Harnett.

 

 In May, the firm also announced the appointment of Robert Vidal to its London office, enhancing its competition law expertise within the life sciences sector.

Latest press releases

Show me all press releases

Pinsent Masons announces new co-heads of Madrid, Inmaculada Castelló and Fernando Gutiérrez

Multinational law firm Pinsent Masons has appointed Inmaculada Castelló and Fernando Gutiérrez as co-heads of the Madrid office as of 1 September 2022.

Pinsent Masons advises UMS Consulting on its acquisition by Expleo

Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.

Pinsent Masons advises climate-tech venture capital fund, Systemiq Capital, on the $70m closing of its second fund

Multinational law firm Pinsent Masons has advised climate-tech VC fund Systemiq Capital on the $70 million first close of its second fund, targeting $200 million to continue backing the best early-stage climate tech entrepreneurs.

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises UMS Consulting on its acquisition by Expleo

Multinational law firm Pinsent Masons has advised the shareholders of UMS Consulting GmbH & Co. KG on the sale of their shares to Expleo Group S.A.S.

Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.

Pinsent Masons launches parallel trade monitoring platform for life sciences sector

Multinational law firm Pinsent Masons launches innovative online tool to help life sciences organisations grappling with parallel trade management.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts